BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

HKeyBio Launches NHP Fast-Tox Program to Accelerate Early Safety Assessment for Biologics

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics an...

June 26, 2026 | News

UniXell Secures US FDA Clearance for Off-the-Shelf Parkinson’s Cell Therapy, Advancing Dual-China-US Clinical Development

UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA...

June 25, 2026 | News

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

China Approves World's First CAR-T Therapy for Solid Tumours

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...

June 24, 2026 | News

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

Samsung Bioepis and Organon Expand Canadian Biosimilars Alliance with PYZCHIVA® Commercialisation Agreement

Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commer...

June 23, 2026 | News

Teijin Pharma Limited and Merz Therapeutics GmbH Win Japanese Approval for XEOMIN® in Cervical Dystonia and Blepharospasm

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurolog...

June 23, 2026 | News

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms 10x...

June 19, 2026 | News

Single Use Support Launches Next-Generation RoSS.BLST Platform for Scalable Freeze-Thaw Bioprocessing

Single Use Support introduces the advanced RoSS.BLST, a blast freezing and thawing platform designed to deliver maximum process consistency and product qua...

June 18, 2026 | News

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast in Lower-Risk Myelodysplastic Syndromes

Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 Ha...

June 17, 2026 | News

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia

Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...

June 17, 2026 | News

Harbour BioMed's Antibody Innovation Prevails in Major Patent Clash with Amgen

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's g...

June 16, 2026 | News

Stay Connected